I have to admit it, up front: I’m just as disgusted with writing about the insanity of transgender “care” for children as you are reading about it, but we’ve reached a point under the Biden presidency where even Europe calls the U.S. an “outlier” among Western nations in respect to so-called “gender-affirming care.”
Who’d a thunk it? Frggin’ Europe, I mean.
If that doesn’t tell you how deep in the sick cesspool Joe Biden has gleefully tried to sink America, what would? Supporting so-called “trans” adults is one thing; supporting the irreversible mutilation of the bodies of confused children is unconscionable.
The inexcusable insanity, described by the Democrat Party as “gender-affirming care” for “trans kids,” includes puberty-blocking drugs, double mastectomies, and castration — both chemically and surgically.
But Europe is shifting away from that approach, leaving the U.S. an outlier in the field.
Who’d a thunk it? Frggin’ Europe, I mean.
If that doesn’t tell you how deep in the sick cesspool Joe Biden has gleefully tried to sink America, what would? Supporting so-called “trans” adults is one thing; supporting the irreversible mutilation of the bodies of confused children is unconscionable.
The inexcusable insanity, described by the Democrat Party as “gender-affirming care” for “trans kids,” includes puberty-blocking drugs, double mastectomies, and castration — both chemically and surgically.
But Europe is shifting away from that approach, leaving the U.S. an outlier in the field.
The U.S. is becoming an outlier among many Western nations in the way its national medical institutions treat children suffering from distress over gender identity.
For years, the American healthcare industry has staunchly defended medical interventions for transgender minors, including puberty blockers, which suppress the physical changes of adolescence as a treatment for those distressed over their gender.
The European medical community, by contrast, is expressing doubts about that approach. Having allowed these treatments for years, five countries—the U.K., Sweden, Finland, Norway, and France — now urge caution in their use for minors, stressing a lack of evidence that the benefits outweigh the risks.
This month, the U.K.’s publicly funded National Health Service limited the use of puberty blockers to clinical trials, putting the drugs beyond the reach of most children.